US Representative

Brad Finstad Authored & Sponsored Legislation

Session

Co-Sponsor of Legislation

US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB620

Introduced
1/22/25  
Refer
1/22/25  
FARM Act Foreign Adversary Risk Management Act
US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB624

Introduced
1/22/25  
RIFLE Act of 2025 Reining In Federal Licensing Enforcement Act of 2025
US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB648

Introduced
1/23/25  
Strengthening our Servicemembers with Milk Act
US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB649

Introduced
1/23/25  
Refer
1/23/25  
Whole Milk for Healthy Kids Act of 2025
US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB650

Introduced
1/23/25  
Families’ Rights and Responsibilities Act
US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB685

Introduced
1/23/25  
Support And Value Expectant Moms and Babies Act of 2025 or the SAVE Moms and Babies Act of 2025This bill prohibits the Food and Drug Administration (FDA) from approving any new drug (either as a brand-name drug or a generic) intended to terminate a pregnancy and imposes additional restrictions on such drugs that are already approved.Under the bill, an already-approved drug intended to terminate a pregnancy may be dispensed to a patient only with a prescription. Furthermore, the FDA may not approve any labeling change that would authorize (1) using the drug after 70 days of gestation, or (2) dispensing the drug by any means other than in-person administration by the prescribing health care practitioner.The FDA must also impose additional restrictions on such already-approved drugs, including by (1) requiring the prescribing health care practitioner to receive a special certification, (2) prohibiting the practitioner from also acting as the dispensing pharmacist, and (3) requiring the practitioner to have the ability to provide surgical intervention to the patient.The bill also rescinds any investigational use exemption already granted to such a drug if the bill would have prohibited the FDA from granting the exemption. (Currently, the FDA may grant an exemption to certain market approval requirements if a drug is intended solely for use in safety and effectiveness investigations.)
US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB689

Introduced
1/23/25  
Refer
1/23/25  
FREE Act Full Responsibility and Expedited Enforcement Act
US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB7

Introduced
1/22/25  
No Taxpayer Funding for Abortion and Abortion Insurance Full Disclosure Act of 2025This bill modifies provisions relating to federal funding for, and health insurance coverage of, abortions.Specifically, the bill prohibits the use of federal funds for abortions or for health coverage that includes abortions. Such restrictions extend to the use of funds in the budget of the District of Columbia. Additionally, abortions may not be provided in a federal health care facility or by a federal employee.Historically, language has been included in annual appropriations bills for the Department of Health and Human Services (HHS) that prohibits the use of federal funds for abortions—such language is commonly referred to as the Hyde Amendment. Similar language is also frequently included in appropriations bills for other federal agencies and the District of Columbia. The bill makes these restrictions permanent and extends the restrictions to all federal funds (rather than specific agencies).The bill's restrictions regarding the use of federal funds do not apply in cases of rape, incest, or where a physical disorder, injury, or illness endangers a woman's life unless an abortion is performed. The Hyde Amendment provides the same exceptions.The bill also prohibits qualified health plans from including coverage for abortions. Currently, qualified health plans may cover abortion, but the portion of the premium attributable to abortion coverage is not eligible for subsidies.
US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB703

Introduced
1/23/25  
Main Street Tax Certainty Act
US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB724

Introduced
1/24/25  
CBO Show Your Work Act This bill requires the Congressional Budget Office (CBO) to make available to Congress and the public each fiscal model, policy model, and data preparation routine that the CBO uses to estimate the costs and other fiscal, social, or economic effects of legislation. For each estimate of the costs and other fiscal effects of legislation, the CBO must also disclose, in a manner sufficient to permit replication by individuals not employed by the CBO, the data, programs, models, assumptions, and other details of the computations used to prepare the estimate. For data that may not be disclosed, the CBO must make available to Congress and the public a complete list of all data variables for the data; descriptive statistics for all data variables for the data, to the extent that the descriptive statistics do not violate the rule against disclosure; a reference to the statute requiring that the data not be disclosed; and contact information for the individual or entity who has unrestricted access to the data.